Objective Gastric cancer(GC)is the fifth most common cancer and the third leading cause of cancer death worldwide.It is imperative to identify GC patients at a high risk for poor prognosis,so that timely and appropriate treatment strategy can be applied.Although a considerable proportion of patients are diagnosed at an advanced stage,patient outcomes can vary significantly even for patients with similar clinical features.The host heterogeneity in somatic or germline changes may have led to different prognosis.